Analysis of 10,953 patient samples across 32 cancer types from the TCGA pan-cancer atlas database revealed that TAS2R9 was altered in 1.9% (211/10,953) of samples with a somatic mutation frequency of 0.5%. This evidence concerns the gene TAS2R9 and cancer.